BUT It's great that these results lay the groundwork for what we all expect from PegpH20- total dominance in High Hyaluronan Cancer with various accompanying chemotherapies.
Highly Allergenic besides the risk of slow virus, in eye anesthesia has cause swelling so great that the optic nerve was threatened. The swelling raises the internal pressure in the eye and prevents surgery from being performed. This is a nonstarter- not in my family! No pharmaceutical company would back it anyway. This is why Hylenex has replaced Bovine and Ovine Hyaluronidase as the leading agent.
Mark Schoenebaum-Analyst Evercore ISI-
I know after the Onyx deal, you wanted to go through a period of deleveraging, where you felt like you probably weren't in a position to do an Onyx type of deal. What about now? How does the balance sheet look now? If an Onyx-sized opportunity came along now, do you believe you've got the financial flexibility to do it? Or do you want to continue to delever? Thanks.
Bob Bradway Chairman and CEO Amgen-
Our focus is on earlier stage transactions that we think can bring innovation to the Company that we can add value to, but we have the flexibility in the balance sheet if attractive opportunities arise that are of the larger size.
I wish Mark asked Bob if it's coincidence that HALO's CEO, CFO, & Board Chair are All ex High Level AMGN Execs- given Helen Torley's visit to ONYX and how it turned out.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Halozyme Therapeutics Inc (Symbol: HALO) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $17.16 per share. By comparison, the current RSI reading of the S&P 500 ETF is 38.0. A bullish investor could look at HALO's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of HALO shares: Halozyme Therapeutics Inc 1 Year Performance Chart
Looking at the chart above, HALO's low point in its 52 week range is $7.51 per share, with $25.25 as the 52 week high point - that compares with a last trade of $17.18.
See Seeking Alpha Q2 2015 Transcript
Helen Torley - President, Chief Executive Officer and member of the Board of Directors
So, our primary focus at the moment us is definitely pancreats, that's obviously where we want to assure everything is very nicely in place and keep -- as it is at the moment not being a rate limiter for Phase III.
But we have expanded our work with Ventana to now start looking also at breast cancer and lung cancer. And we're working separately on that. I think it's a little early for us to say if the cut point will be the same between these three tumors. What we are doing with Ventana is evaluating samples to look and see. So, you'll have to stay tuned for that update, Arlinda, but I can say we're very pleased working with Ventana. Obviously, we picked them because they are leader in the fields and that we're findings this to be an extremely productive and collaborative relationship as we expand beyond pancreatic cancer into leukemia, breast, and lung as well.
Thanks for the advice- I lost 2 followers this weekend over the politics- But I had to get it off my chest- I agree with you that in the best interests of being heard on HALO, the politics should be placed aside. Once the emperor has been called naked, it doesn't have to be repeated- hopefully others will be inspired to demand better from our potential public servants. Now, what do YOU predict for HALO earnings tomorrow?
3 Amgen alums in top leadership 2 Cardinal Healths in Business positions...small-mid size company
Accelerated approval has always been a probable outcome for 202 data- especially if LMW Heparin adds as much to efficacy as it did to safety. MNTA's whole PDA program is based on an analogue of LMW Heparin. It only takes the DMC to halt on efficacy.
We may even see dome mabTheraSC Royalty cash this quarter.
Yes you're right- but there is less than a 1% chance that any single biotech or Big Pharma would be so represented in the leadership of a small-midcap- so I'm intrigued, while I hope it's just the familiarity of former colleagues that brings them together
There is no speculation in that comment- pure fact. Given the way Amgen bought ONXX following a 2 year stint by Helen Torley who left AMGN 8/11 to be CCO and returned- after buyout 8/13- to AMGN-I will speculate that Santayana knew what he was saying. I would prefer for HALO to remain independent, but the CFO hire reminds me of ONXX.
right regressions- thanks- 6/7 w peg- the point is the telegraphing of what's to come- shIDO-ST Paper with plan to enter clinic? - check- Eisai Halaven collaboration w PegpH20? check- 3rd slide in Analyst presentation- T cell and NK cell access into solid tumors- Gimme a Big Check on that one HALO and I'm good.
Look at the Slide of Halaven and PegpH20 preclinical work at the Jan 7 Analyst day- amazing results- 6/7 CRs. HALO telegraphed this deal AND the City of Hope shIDO-ST research in those slides- what else? Oh, just the one on how PegpH20 gains T cells and NK cells solid tumor access- That might have some importance soon- not to put the horse before the CAR-T.
The Biggest "All talk" move in this arena was CS Behring's last minute effort to stop HyQvia with "A Citizen's Petition" No one in their right mind would have believed a trumped up "titer argument" would have ever persuaded anyone without an ulterior motive-Of Course it failed.